Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066957 · ClinicalTrials.gov registry record · Phase 2
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
A Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06066957: Recruiting Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder, sponsored by University of Pennsylvania.
NCT06066957 is a Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 80 participants, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06066957, a Phase 2 study of Cytomegalovirus Infections and Transplant-Related Disorder, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients. The study hypotheses are: 1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients 2. Letermovir will be better tolerated than valganciclovir for CMV prophylaxis in heart and lung transplant recipients, with a higher proportion of days of completed therapy with correct dosing during the planned prophylaxis period 3. Letermovir will have a lower rate of neutropenia than valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients 4. Incorrect renal dosing will occur less frequently with letermovir than with valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients
Primary Outcome
The primary outcome will be CMV infection (CMV viremia with CMV viral load \>1,000, CMV syndrome, or tissue invasive CMV disease) during the planned prophylaxis period and the following 180 days
Conditions Studied
Interventions
- DRUG Letermovir 480 MG [Prevymis]
Study Locations (1)
Pennsylvania
- Penn Medicine at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2026-08-15 |
| Phase | Phase 2 |
What NCT06066957 shows while recruiting
NCT06066957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Letermovir 480 MG [Prevymis] is the first listed.
NCT06066957 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06066957 about?
NCT06066957 is a clinical study titled "Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients". Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients. The study hypotheses are: 1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients ...
What is the current status of trial NCT06066957?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-04-04. Estimated completion is 2026-08-15.
What conditions does trial NCT06066957 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Transplant-Related Disorder.
What interventions are being tested in trial NCT06066957?
The interventions under investigation include: Letermovir 480 MG [Prevymis] (DRUG).
Who is sponsoring clinical trial NCT06066957?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066957 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06066957's enrollment target sits among peer trials
80 12th of 24 higher than 12 of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
COMPLETED · Phase 2
-
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
COMPLETED · Phase 2
-
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
COMPLETED · Phase 2
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI